INTRODUCTION

An increased incidence of non-Hodgkin's lymphoma has been reported in patients with inflammatory bowel disease, particularly in those receiving immnosuppressive therapy. This complication generally arises in sites of active inflammatory disease. We report an unusual case of diffuse large B-cell lymphoma complicating an ileocolic Crohn's disease, which appeared suddenly and became widespread rapidly. The diagnosis was confirmed by peritoneal cytology with immunochemistry.

The association between Crohn's disease and malignancy is well documented. The risk of developing small bowel adenocarcinoma is slightly increased in patients with Crohn's disease. However, the association between Crohn's disease and non-Hodgkin's lymphoma remains controversial as the number of cases is not big enough to establish a definitive relationship. Intestinal lymphoma generally arises in long-standing Crohn's disease, in locations where the inflammatory disease is highly active. In this paper, we report an unusual case of Diffuse large B-cell lymphoma in a patient with an 18-year history of ileocolic Crohn's disease.

CASE REPORT

A 42-year-old woman with an 18-year history of Crohn's disease presented with malnutrition and abdominal pain. She had been intermittently treated with corticosteroids and azathioprine and had been hospitalized on multiple occasions for intermittent small bowel obstruction.

A colonoscopy performed four months earlier had revealed the appearance of a severe flare of ileocolic Crohn's disease with probable ileal stenosis. The histological examination had shown catarrhal colitis with signs of chronic Crohn's disease. Computed tomography (CT) with contrast revealed a symmetric circumferential thickening of the intestinal wall in the last ileal segment related to Crohn's disease.

She presented to the clinics with a two-week history of abdominal pain, vomiting, and weight loss. Upon hospital admission, her vital signs were blood pressure 130/70 mm Hg, pulse 100 beats/min, and temperature 38.6°C. Her body mass index (BMI) was calculated at 22 kg/m². Abdominal examination found diffuse tenderness and distention with ascites. The laboratory data, summarized in Table 1, showed abnormally elevated inflammatory markers (CRP = 310, WBC = 11 050). An abdominal and chest contrast CT revealed an irregular,
circumferential thickening of the intestinal wall in last ileal segment, multiple mesenteric and abdominal lymph nodes with malignant ascites, and multiple vertebral osteolytic lesions (Figure 1). This aspect called to mind a lymphomatous transformation with peritoneal carcinomatosis and bone metastases. Ascites cytology with immunochemistry concluded to large B-cell lymphoma with positive CD20 (Figures 2-4). The patient developed acute kidney failure with severe metabolic acidosis. She died several days later due to pulmonary edema.

### DISCUSSION

Primary malignant lymphoma of the gastrointestinal tract is rare.3 Most cases occur in the stomach, but sometimes the small bowel and colon are involved. Inflammatory bowel disease (IBD), especially ulcerative colitis, is known to increase the risk of adenocarcinoma which presents with extensive bowel involvement and persistent colitis.4 However, primary gastrointestinal lymphoma was rarely reported in association with IBD, being more common in chronic ulcerative colitis. Shepherd et al5 reported seven cases associated with ulcerative colitis and three cases associated with Crohn’s disease.

Adrian et al6 reported that the risk factors for colonic lymphoma in UC were, in three principal aspects, similar to those of colitis-related colonic adenocarcinoma: younger age at cancer onset, universal colitis, and long-standing quiescent disease. In contrast, lymphomas in Crohn’s disease occurred within 10 years of the initial diagnosis,5 and small bowel lymphoma was more frequent. Early diagnosis of lymphoma is challenging because of the similar radiologic appearance with Crohn’s disease.8 Non-Hodgkin’s lymphoma is more frequent than Hodgkin’s lymphoma in IBD.7 Tumors in Crohn’s disease are aggressive since they are high grade. Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of aggressive lymphomas and has a lower survival rate than MALT lymphoma.11 The prognosis and management of this tumor depend on the staging. Patients at lower stages (I and II) had a longer cumulative survival than patients at stage III or IV.12 Containing-strategy chemotherapy may be the optimal choice for intestinal DLBCL.12

Even though association between Crohn’s disease and lymphoma is uncertain, some findings support its existence including the fact that the majority of reported tumors have arisen at sites of active inflammatory bowel disease (intestinal tract).5 A possible factor in the genesis of lymphoma is immunosuppression. In fact, a published meta-analysis showed a fourfold increased risk of non-Hodgkin’s lymphoma in a subgroup of IBD patients treated with azathioprine and/or 6-mercaptopurine.9 Other mechanisms can also explain this association including primary immunologic defects associated with IBD. Auen et al showed that certain patients with Crohn’s disease may have deficits in both T- and B-lymphocyte populations secondary to the high activity and chronicity of the disease.10 Besides, frequent exposure to X-rays increases the risk of lymphoma.6 Our patient had large cell lymphoma, known to occur exclusively with

### TABLE 1 Laboratory data

| Laboratory tests                  | Day 1 of admission | Day 7 |
|-----------------------------------|--------------------|-------|
| Hemoglobin (g/dL)                 | 9.8                | 9.1   |
| Platelet Count                    | 383 000            | 370 000 |
| White blood cell count            | 8130               | 11 050 |
| Prothrombin time (%)              | 100                | 84    |
| Asparate aminotransferase (U/L)   | 33                 | —     |
| Alaminotransferase (U/I)          | 13                 | —     |
| Total bilirubin (mg/L)            | 11                 | —     |
| Alkaline phosphatase (U/I)        | 75                 | 756   |
| Creatinine (mg/L)                 | 74                 | 139   |
| Sodium (mEq/L)                    | 138                | 3.2   |
| Potassium (mEq/L)                 | 4.5                | 22    |
| C-reactive protein (mg/L)         | 310                | —     |
| Creatinine phosphokinase (UI/L)   | 42                 | —     |
| Lactic acid dehydrogenase (UI/L)  | 1475               | —     |
| Corey embryonic antigen (ng/mL)   | 2.7                | —     |
| Albuminemia (g/L)                 | 25                 | —     |
| pH                                | 7.47               | 7.24  |
| \(\text{PaO}_2\)                  | 80                 | 125   |
| \(\text{PCO}_2\)                  | 34                 | 18    |
| \(\text{HCO}_3^-\)                | 24.7               | 7.7   |
immunosuppression-induced lymphoma. In fact, she had been treated with corticosteroids and azathioprine for many years.

Some patients did not receive azathioprine or prednisone before diagnosis of the lymphoma, so these medications could not have played an essential role in the development of lymphoma.6

4 | CONCLUSION

There is good evidence that malignant lymphoma of the bowel is a rare but significant complication of inflammatory bowel disease, apparently more common in chronic ulcerative colitis. Since the prognosis of lymphoma depends on the stage of the disease at the time of diagnosis, we suggest meticulous monitoring to diagnose the disease early so that treatment can be initiated promptly, which can have significant benefits.

ACKNOWLEDGMENT
Published with written consent of the patient.

CONFLICTS OF INTEREST
None declared.

AUTHOR CONTRIBUTIONS
SM and BFF: wrote the manuscript. BN and OA: held the patient in the department. KF: provided the cytology examination results and pictures. GD: reviewed the manuscript.

ORCID
Meriam Sabbah [https://orcid.org/0000-0001-5225-8271]

REFERENCES
1. Perosio PM, Brooks JJ, Saul SH, Haller DG. Primary intestinal lymphoma in Crohn’s disease: minute tumor with a fatal outcome. Am J Gastroenterol. 1992;87(7):894-898.
2. Weingrad DN, Decosse JJ, Sherlock P, Straus D, Lieberman PH, Filippa DA. Primary gastrointestinal lymphoma: a 30-year review. Cancer. 1982;49(6):1258-1265.
3. Lennard-Jones JE, Melville DM, Morson BC, Ritchie JK, Williams CB. Precancer and cancer in extensive ulcerative colitis: findings among 401 patients over 22 years. Gut. 1990;31(7):800-806.
4. Shepherd NA, Hall PA, Williams GT, et al. Primary malignant lymphoma of the large intestine complicating chronic inflammatory bowel disease. Histopathology. 1989;15:325-337.
5. Farrell RJ, Ang Y, Kileen P, et al. Increased incidence of non-Hodgkin’s lymphoma in inflammatory bowel disease patients on immunosuppressive therapy but overall risk is low. Gut. 2000;47:514-519.
6. Sartoris DJ, Harell GS, Anderson MF, Zboraľské FF. Small-bowel lymphoma and regional enteritis: radiographic similarities. Radiology. 1984;152:291-296.
7. Kandiel A, Fraser AG, Korelitz BI, Brensinger C, Lewis JD. Increased risk of lymphoma among inflammatory bowel disease patients on immunosuppressive therapy. Gut. 1990;31(7):800-806.

FIGURE 2  Histological examination of ascites: HE (×400) lymphoid proliferation

FIGURE 3  Positivity of immunostaining Ki-67 (×400)

FIGURE 4  Positivity of immunostaining Mum1 (×400)
patients treated with Azathioprine and 6-mercaptopurine. *Gut*. 2005;54(8):1121-1125.

8. Auer IO, Götz S, Ziemer E, Malchow H, Ehms H. Immune status in Crohn's disease. Peripheral blood B lymphocytes, enumerated by means of F(ab)2-antibody fragments, Null and T lymphocytes. *Gut*. 1979;20:261-268.

9. Li B, Shi YK, He XH, et al. Primary non-Hodgkin lymphomas in the small and large intestine: clinicopathological characteristics and management of 40 patients. *Int J Hematol*. 2008;87(4):375-381.

10. Yin L, Chen CQ, Peng CH, et al. Primary small-bowel non-Hodgkin's lymphoma: a study of clinical features, pathology, management and prognosis. *J Int Med Res*. 2007;35(3):406-415.

11. Siegel CA. Risk of lymphoma in inflammatory bowel disease. *Gastroenterol Hepatol (N Y)*. 2009;5(11):784-790.

12. Loftus EV Jr, Tremaine WJ, Harbermann TM, Harmsen WS, Zinsmeister AR, Sandborn WJ. Risk of lymphoma in inflammatory bowel disease. *Am J Gastroenterol*. 2000;95:2308-2312.

**How to cite this article:** Sabbah M, Ben Farhat F, Bellil N, Khanchel F, Ouakaa A, Gargouri D. An unusual case of diffuse large B-cell lymphoma complicating a Crohn's disease. *Clin Case Rep*. 2020;8:3061–3064. [https://doi.org/10.1002/ccr3.3364](https://doi.org/10.1002/ccr3.3364)